GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » Return-on-Tangible-Asset

Hisamitsu Pharmaceutical Co (TSE:4530) Return-on-Tangible-Asset : 4.39% (As of Nov. 2023)


View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Hisamitsu Pharmaceutical Co's annualized Net Income for the quarter that ended in Nov. 2023 was 円14,772 Mil. Hisamitsu Pharmaceutical Co's average total tangible assets for the quarter that ended in Nov. 2023 was 円336,361 Mil. Therefore, Hisamitsu Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Nov. 2023 was 4.39%.

The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:

TSE:4530' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.06   Med: 6.37   Max: 7.48
Current: 4.29

During the past 13 years, Hisamitsu Pharmaceutical Co's highest Return-on-Tangible-Asset was 7.48%. The lowest was 3.06%. And the median was 6.37%.

TSE:4530's Return-on-Tangible-Asset is ranked better than
60.5% of 1081 companies
in the Drug Manufacturers industry
Industry Median: 1.84 vs TSE:4530: 4.29

Hisamitsu Pharmaceutical Co Return-on-Tangible-Asset Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co Return-on-Tangible-Asset Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.23 3.06 3.22 3.82 4.40

Hisamitsu Pharmaceutical Co Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.74 5.12 5.27 4.39 2.28

Competitive Comparison of Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset falls into.



Hisamitsu Pharmaceutical Co Return-on-Tangible-Asset Calculation

Hisamitsu Pharmaceutical Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Feb. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Feb. 2024 )  (A: Feb. 2023 )(A: Feb. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Feb. 2024 )  (A: Feb. 2023 )(A: Feb. 2024 )
=13969/( (312972+321949)/ 2 )
=13969/317460.5
=4.40 %

Hisamitsu Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Nov. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Nov. 2023 )  (Q: Aug. 2023 )(Q: Nov. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Nov. 2023 )  (Q: Aug. 2023 )(Q: Nov. 2023 )
=14772/( (343376+329345)/ 2 )
=14772/336360.5
=4.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Nov. 2023) net income data.


Hisamitsu Pharmaceutical Co  (TSE:4530) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Hisamitsu Pharmaceutical Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Traded in Other Exchanges
Address
408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines